Studies by Hashemi et al. (2009) and Wah Kheong et al. (2017) further underscored silymarin's efficacy in reducing serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and in achieving fibrosis reduction based on histology and liver stiffness measurements, suggesting its role in fibrosis management in non-alcoholic steatohepatitis (NASH) patients [9,10]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.